The research, published in Toxicology Reports, indicates that Nixodine-S—chemically identified as (S)-6-methylnicotine—functions effectively at key nicotinic acetylcholine receptors. Specifically, the molecule demonstrated comparable potency to nicotine at the α4β2 and α3β4 subtypes, which are associated with reward pathways. Notably, the substance showed substantially lower potency at the α6/3β2β3 receptor subtype, a critical component in dopamine amplification, suggesting a distinct pharmacological profile compared to traditional nicotine.
Bonguard Naturals Unveils Nixodine-S as a Potential Nicotine Alternative
Bonguard Naturals has introduced Nixodine-S, a patented, non-tobacco-derived molecule designed to replace nicotine in adult vapor and oral products. A recent nonclinical study suggests this substance can replicate the satisfaction-related receptor activity of nicotine while demonstrating significantly lower cytotoxicity in laboratory-controlled, volume-equivalent testing environments.
From a manufacturing perspective, the formulation is engineered to serve as a volume-for-volume substitute, allowing companies to integrate the ingredient into existing production lines without significant infrastructure changes. Rick Avila, CEO and founder of Bonguard Naturals, stated that the industry has historically focused on delivery systems rather than the molecule itself, noting that this research provides a scientific foundation for moving beyond conventional nicotine. While the in vitro results showed no evidence of genotoxicity or mutagenicity, the company emphasizes that these findings do not yet establish clinical safety in humans, and further research is required to evaluate the long-term implications of the substance.
Comments (0)
No comments yet. Be the first!